Cargando…
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis
BACKGROUND: Autologous mesenchymal stem cell neurotrophic factor–secreting cells (NurOwn(®)) have the potential to modify underlying disease mechanisms in progressive multiple sclerosis (PMS). OBJECTIVE: This open-label phase II study was conducted to evaluate safety/efficacy of three intrathecal ce...
Autores principales: | Cohen, Jeffrey A, Lublin, Fred D, Lock, Christoper, Pelletier, Daniel, Chitnis, Tanuja, Mehra, Munish, Gothelf, Yael, Aricha, Revital, Lindborg, Stacy, Lebovits, Chaim, Levy, Yossef, Motamed Khorasani, Afsaneh, Kern, Ralph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896300/ https://www.ncbi.nlm.nih.gov/pubmed/36113170 http://dx.doi.org/10.1177/13524585221122156 |
Ejemplares similares
-
MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model
por: Kaspi, Haggai, et al.
Publicado: (2021) -
miRNA profiling of NurOwn®: mesenchymal stem cells secreting neurotrophic factors
por: Gothelf, Yael, et al.
Publicado: (2017) -
A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis
por: Cudkowicz, Merit E., et al.
Publicado: (2022) -
NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results
por: Berry, James D., et al.
Publicado: (2019) -
Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells
por: Gothelf, Yael, et al.
Publicado: (2014)